Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Rituximab in Refractory Myasthenia Gravis
NCT05332587Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in myasthenia gravis (MG), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Time to reach Mild Clinical Manifestations (MM-1) at 27 weeks. Status: unknown.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05332587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332587.